GRM5 and fragile X syndrome: The metabotropic glutamate receptor 5 (mGluR5) is predicted to be a therapeutic drug target for FXS (Levenga et al., 2011; Vinueza Veloz et al., 2012; Pop et al., 2014; Scharf et al., 2015).